Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Rubius Therapeutics Inc (RUBY) COM USD0.001

Sell:$18.24 Buy:$18.34 Change: $0.78 (4.09%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.78 (4.09%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.78 (4.09%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Rubius Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. It develops RCT product candidates based on therapeutic modalities such as immune system stimulation for the treatment of cancer and immune modulation to induce tolerance in autoimmune diseases. Its oncology program, RTX-240, is in the Phase I/II clinical trial for relapsed/refractory or solid tumors and in the Phase I clinical trial for relapsed/refractory acute myeloid leukemia (AML). Its artificial antigen presenting cell (aAPC) program, RTX-321, is in the Phase I clinical trial for the treatment of advanced human papillomavirus (HPV) 16-positive cancers.

Contact details

399 Binney St Ste 300
United States
+1 (617) 6799600

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.67 billion
Shares in issue:
89.77 million
United States
US dollar

Key personnel

  • David Epstein
    Chairman of the Board
  • Pablo Cagnoni
    President, Chief Executive Officer, Director
  • Jose Carmona
    Chief Financial Officer
  • Dannielle Appelhans
    Chief Operating Officer
  • Laurence Turka
    Chief Scientific Officer
  • Christina Coughlin
    Chief Medical Officer
  • Jim Jogerst
    Chief Business Officer
  • Maiken Keson-Brookes
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.